Corcept Therapeutics Incorporated (CORT) AI Stock Analysis

Corcept Therapeutics Incorporated specializes in the discovery, development, and commercialization of pharmaceuticals targeting severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Its core commercial product is Korlym (mifepristone) tablets, an oral medication for adult patients with hyperglycemia caused by hypercortisolism associated with endogenous Cushing's syndrome who have failed surgery or cannot undergo surgery. The company's pipeline includes relacorilant for Cushing's syndrome and advanced ovarian tumors, selective cortisol modulators for metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, and FKBP5 gene expression assays.

Corcept expanded annual revenue from $366.0M in FY2021 to $401.9M in FY2022, $482.4M in FY2023, $675.0M in FY2024, and $761.4M in FY2025, recording a 5-year revenue CAGR of 16.6%. Annual gross margin remained steady at 98.3% in FY2025, while operating margin fell from 34.0% in FY2021 to 5.9% in FY2025 as research and development expense grew to $254.9M. Net income stood at $99.7M in FY2025 with diluted EPS of $0.82. In the latest quarter ended June 30, 2026, revenue increased 31.7% year-over-year, and earnings grew 24.1%, supporting trailing twelve-month revenue of $830.8M.

As of June 30, 2026, Corcept held $308.2M in cash and short-term investments against $9.4M in total debt, yielding net cash of $298.8M. The company reported total assets of $888.7M, shareholders' equity of $705.8M, a current ratio of 2.86, and a debt-to-equity ratio of 0.01. Operating cash flow reached $142.0M in FY2025, with free cash flow of $141.8M and capital expenditures of $211,000. Capital allocation in FY2025 included $245.9M deployed toward share buybacks.

Corcept closed at $110.16 on October 16, 2026, giving it a market capitalization of $11.91B and an enterprise value of $11.89B. The stock trades at a trailing P/E of 244.8x compared to the median of 24.6x for its US-listed Healthcare peers. Its forward P/E is 19.3x versus the peer median of 17.3x, while its price-to-sales ratio sits at 14.3x versus the peer median of 4.1x. Over the past year, the stock returned 38.6%, outperforming the S&P 500 return of 16.8%, and gained 449.7% over 5 years compared to 83.0% for the S&P 500.

Wall Street coverage includes 3 Strong Buy, 1 Buy, and 1 Strong Sell ratings. The mean price target of $141.00 represents a 28.0% premium over the last close of $110.16. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $1.15B and EPS of $2.12, reflecting expected EPS growth of 158.5%. For the next fiscal year, 4 analysts estimate revenue of $1.71B and EPS of $4.41. The company beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 3, 2026.

This page is an AI-written research summary of Corcept Therapeutics Incorporated (CORT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CORT income statement, CORT balance sheet, CORT key metrics, CORT analyst forecast, CORT chart. See the CORT stock overview for the latest quote and news.